More than decades have already elapsed since human immunodeficiency virus (HIV) was identified as the causative agent of acquired immunodeficiency syndrome (AIDS). The HIV has since spread to all parts of the world with devastating effects. In sub-saharan Africa, the HIV/AIDS epidemic has reached unprecedented proportions. Safe, effective and affordable HIV/AIDS vaccines for Africans are therefore urgently needed to contain this public health problem. Although, there are challenges, there are also scientific opportunities and strategies that can be exploited in the development of HIV/AIDS vaccines for Africa. The recent RV144 Phase III trial in Thailand has demonstrated that it is possible to develop a vaccine that can potentially elicit modest protective immunity against HIV infection. The main objective of this review is to outline the key scientific opportunities, challenges and strategies in HIV/AIDS vaccine development in Africa.
Introduction
Since the human immunodeficiency virus (HIV) was previously identified as the etiologic agent for acquired immunodeficiency syndrome (AIDS) more than three decades ago, the virus has spread to almost all parts of the world [1] . Globally, more than 34 The recent Thailand's RV144 phase-III trial has shown that it is possible to develop a vaccine that can induce some protective immune responses against HIV acquisition [3] .
Methods
This was not a systematic review. So medical literature related to HIV/AIDS vaccines and other aspects of HIV in Africa was searched unsystematically. From the database, PubMed, specific search approaches were used. We searched the literature using keywords such as "HIV vaccines", "HIV immune responses", "HIV vaccines in T cells which can play important roles in provoking immunity to a variety of pathogens including HIV [39] . Studies have demonstrated the presence of SIV-and HIV-specific CD8+ T cell responses in the genital tracts of infected macaques [40] . Inducing humoral, CD8+ and CD4+ T cell responses at mucosal surfaces with vaccines can potentially prevent or control HIV replication in the mucosal lymphoid tissue. One of the key advantages of mucosal vaccination against HIV is that mucosal immunity protects systemic infection, whereas systemic immunity poorly protects against mucosal infection [41] . The other advantage of mucosal vaccination is that antigenic exposure at one mucosal site activates B and T cells to emigrate and home to other mucosal surfaces, thereby conferring protection at these sites [42] . Protective vaccine-induced mucosal immunity against HIV has been demonstrated in animal models [43] . Therefore the challenge is to develop HIV vaccines for Africa that can induce both B and T cell responses in mucosal tissues.
Immune correlates of HIV protection in Africa
To date, the exact immune correlates of protection against natural protection against simian AIDS disease in monkeys [45, 46] . Although CD8+ T cell and neutralizing antibodies are considered important for HIV protection or control of infection, the RV144 trial has demonstrated that non-neutralizing antibodies are also crucial [3] . Non-neutralizing antibodies can mediate antibody-dependent cellular cytotoxicity (ADCC), thereby protecting against HIV infection [47] . ADCC is important because it is associated with reduced HIV/AIDS diseases progression and prevention of cell-to-cell spread by the virus [48] . However, the rise of ADCC-escape HIV variants can be a scientific challenge to HIV/AIDS vaccine development [49] .
Another key challenge is that antibodies mediated via complement system or Fc receptors can unfortunately facilitate the infectivity of the HIV [50] . Recombinant plasmids, when used as DNA vaccines induce immune responses specific to the antigen genes carried [72] . Most HIV DNA vaccines have been shown to be safe and to induce protective immune responses in animal models [73, 74] . Induction of both CD8+ CTL and humoral immune responses were demonstrated in animals primed with gp120 DNA vaccine and boosted with gp120 subunit vaccine [75] . A number of candidate DNA vaccines for HIV-1 have already been developed and some tested in Africa for immunogenicity [76] [77] [78] . Such vaccines are likely to be useful in Africa since they induce strong immune responses especially if they are used in prime-boost strategies. Recombinant live viruses can be exploited as vaccine vectors for heterologous antigens [79, 80] Effective anti-HIV immunity, sometimes protective, has been observed in a number of animal studies in which vectors such as adenovirus, alphavirus, sendai virus, herpes simplex virus, human rhinovirus and polio virus were used to express HIV antigens [82] [83] [84] [85] [86] . Recombinant viral vectors therefore seem to offer great opportunities for vaccine development for Africans because of their ability to induce strong HIV-specific immune responses.
Recombinant bacteria can also be used to deliver heterologous antigens to the host's immune system [87] . Their potential use as candidate HIV vaccine vectors to deliver either HIV antigens or HIV DNA vaccines is currently being increasingly studied. Recombinant Bacillus Calmette-Guerin (BCG) expressing HIV antigens has been shown to induce antigen-specific immune responses in vaccinated animals [88] . BCG is generally a good vaccine vector for HIV/AIDS because of a number of reasons such as its known safety record [89] . Another attractive bacterial vaccine vector for HIV/AIDS is Listeria monocytogenes [90] . The key advantage of Listeria as a vaccine vector is that it replicates in the cytosol, thereby inducing both strong CD8+ and CD4+ T cell responses. Shigella is also an attractive vector that is capable of replicating in the cytosol thereby inducing strong cellular immune responses [91] .
Attenuated Shigella strains have already been successfully used to deliver HIV DNA vaccines, resulting in induction of HIV-specific CD8+ T responses [92] . Recombinant Salmonella has also a great potential as a vaccine vector for HIV [93] [94] [95] . Therefore, recombinant bacterial vaccine vectors can be harnessed in the development of HIV/AIDS vaccines for Africa.
Candidate HIV/AIDS vaccines for Africa can be used in prime-boost strategies in order to improve their potency and effectiveness. In these strategies, one vaccine is used to prime the immune system and the second vaccine is used to boost the response [96, 97] . A number of candidate HIV/AIDS vaccines have already been tested in a prime-boost strategy and have been shown to induce good responses [98, 99] . DNA vaccines have already been shown to be best at priming and recombinant viral vectors such as poxvirus vectors are good at boosting the immune responses [100] . Even the Thailand's RV144 phase-III trial used the prime-boost strategy in which a recombinant canarypox vector-based candidate was used in combination with an engineered HIV-1 gp120 protein [3] .
Conclusion
The HIV/AIDS remains a serious public health problem in Africa and development of safe, effective and affordable vaccines for the region remains a daunting challenge. However, a number of efforts have already been done to develop candidate vaccines. 
